Quarterly ResultMay 5, 2026, 04:41 PM
Theriva Biologics Q1 Net Loss $(2.04)M; Cash $14.4M
AI Summary
Theriva Biologics reported its first-quarter 2026 financial results, showing a reduced net loss of $(2.04) million and a cash position of $14.4 million, providing a runway into Q1 2027. The company also announced significant operational progress, including alignment with the FDA on the Phase 3 trial design for VCN-01 in metastatic PDAC and the initiation of compassionate use for VCN-01 in retinoblastoma patients. R&D expenses decreased significantly due to the completion of the VIRAGE Phase 2b trial, while G&A expenses increased.
Key Highlights
- Net Loss for Q1 2026 was $(2.04) million, down from $(4.32) million in Q1 2025.
- Cash and cash equivalents totaled $14.4 million as of March 31, 2026, with a runway into Q1 2027.
- Research and development expenses decreased 88% to $355,000 in Q1 2026 from $3.0 million in Q1 2025.
- General and administrative expenses increased 43% to $2.1 million in Q1 2026 from $1.4 million in Q1 2025.
- License Revenue for Q1 2026 was $300,000, up from $0 in Q1 2025.
- FDA aligned on major elements of proposed pivotal Phase 3 trial design for VCN-01 in metastatic PDAC.
- VCN-01 administered to retinoblastoma patients under compassionate use for dosing feasibility and tolerability data.
Price Impact
More from TOVX